Horizon Therapeutics Plc
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$51Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
56,591clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Krystexxa $6.0M associated (2023-2025)
- Tepezza $5.4M associated (2023-2025)
- Uplizna $3.0M associated (2023-2025)
- Actimmune $280K associated (2023-2025)
- Procysbi $242K associated (2023-2025)
- Ravicti $194K associated (2023-2025)
- Rayos $335 associated (2023-2025)
- Pennsaid $205 associated (2023-2025)
- Buphenyl $43.54 associated (2023-2025)
- Duexis $4.29 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Terry Smith | Ann Arbor, MI | Internal Medicine | $1,751,714.96 |
| Jeff Peterson | Bothell, WA | Rheumatology | $1,712,804.53 |
| John Botson | Anchorage, AK | Rheumatology | $1,667,604.97 |
| Peter Lipsky | Charlottesville, VA | Rheumatology | $1,276,468.40 |
| Raymond Douglas | Beverly Hills, CA | Ophthalmology | $1,248,579.71 |
| Sanjay Chabra | El Paso, TX | Rheumatology | $682,813.87 |
| John Cozzarelli | Belleville, NJ | Foot & Ankle Surgery | $642,128.51 |
| Abdul Abdellatif | Webster, TX | Nephrology (Internal Medicine) | $524,971.31 |
| Payam Shakouri | Poughkeepsie, NY | Nephrology (Internal Medicine) | $476,094.30 |
| Orrin Troum | Santa Monica, CA | Rheumatology | $370,042.67 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.